Study on the Correlation Between ANCA and Thyroid-related Ophthalmopathy
International Journal of Ophthalmology & Visual Science
Volume 5, Issue 1, March 2020, Pages: 21-23
Received: Dec. 16, 2019; Accepted: Jan. 2, 2020; Published: Jan. 17, 2020
Views 117      Downloads 47
Authors
Yuping Xiong, Department of Ophthalmology, The First Affiliated Hospital of Hunan Normal University/Hunan Provincial People’s Hospital, Changsha, China
Changfu Peng, Department of Ophthalmology, Hunan Provincial People’s Hospital/The First Affiliated Hospital of Hunan Normal University, Changsha, China
Article Tools
Follow on us
Abstract
Background The pathogenesis of thyroid associated ophthalmopathy (TAO) is still unclear. Studies have proved that there are several autoantibodies in TAO patients, and ANCA, as one of the autoantibodies, is positive in some TAO patients, but its correlation with the occurrence, development and outcome of TAO is still unclear. Objective To study the correlation between ANCA and Thyroid Associated Ophthalmopathy. Methods Prospective observational cohort study was designed. This study was approved by the Ethic Commission of Hunan Provincial People’s Hospital/the First Affiliated Hospital of Hunan Normal University, and written informed consent was obtained from each Subject before entering this trial. 120 patients diagnosed as TAO and visited our hospital from January 2016 to June 2018 were enrolled in the study, including 30 cases in inactive group and 90 cases in active group [According to the criteria of clinical activity score (CAS)], 42 cases in Mild group and 78 cases in Moderate-to-severe and Sight-threatening group (According to the criteria of EUGOGO). The differences in ANCA positive rate among above groups and Active group after transferred to Inactive were compared. Results The overall positive rate of ANCA in TAO patients was 16.7%. The positive rates in the Inactive group and Active group were respectively 3.33% and 21.11%, and the difference was statistically significant (P<0.05). The positive rates of Mild group, Moderate-to-severe group and Sight-threatening group were respectively 8.82% and 19.76%, and there was no significant differences statistically (P>0.05). The positive rates of Active group reduced to 5.5%, and the difference was statistically significant (P<0.05). Conclusion ANCA can reflects the activity of TAO to some extent, which is helpful to guide clinical treatment and prognosis judgment.
Keywords
Antineutrophil Cytoplasmic Antibody, Thyroid Associated Ophthalmopathy, Correlation
To cite this article
Yuping Xiong, Changfu Peng, Study on the Correlation Between ANCA and Thyroid-related Ophthalmopathy, International Journal of Ophthalmology & Visual Science. Vol. 5, No. 1, 2020, pp. 21-23. doi: 10.11648/j.ijovs.20200501.14
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Xiong Wei, Tan Jia, Peng Changfu. Individualized comprehensive diagnosis and treatment of thyroid-related ophthalmopathy [M]. Changsha: Central South University Press, 2014: 1-19.
[2]
Qian Yu, Li Yuzhen, Liang Wenjun, et al. Research and treatment progress of thyroid-related ophthalmopathy [J]. Advances in Modern Biomedicine 2017; 17 (16): 3195-3200. DOI: 10.13241/j.cnki.pmb.2017.16.048.
[3]
Fu Dian, Liu Yi, Wang Jian. Research progress on thyroid-related ophthalmopathy and autoantigens [J]. Medical Review, 2012, 18 (9): 1374-1376. DOI: 10.3969/j.issn.1006-2084.2012.09.035.
[4]
Feng Xiaoting, Li Zhangfang, Shen Jie: Progress in the diagnosis and treatment of thyroid-related ophthalmopathy. [J]. Chinese Journal of Practical Internal Medicine 2019, 39 (04): 384-388.
[5]
Luoqing Li TAO [M] Beijing: People's Medical Publishing House, 2005: 301.
[6]
Stan MN, Garrity JA, Bahn RS. The evaluation and treatment of graves ophthalmopathy [J]. Med Clin North Am, 2012, 96 (2): 311-28. DOI: 10.1016/j.mcna.2012.01.014.
[7]
Bartalena L, Baldeschi L, Boboridis K. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves Orbitopathy [J]. Eur Thyroid J, 2016, 5 (1): 9-26. DOI: 10.1159/000443828.
[8]
Tan Liming, Jiao Anjun, Feng Xiaojing, Xu Yanyue, Tan Fuyan, He Siqi, Luo Yan, Chen Juanjuan, Jiang Yongqing, Li Hua: Clinical value of antineutrophil cytoplasmic antibody detection for systemic vasculitis. [J]. Laboratory Medicine 2018, 33 (02): 101-105.
[9]
Li Li, Ruofen Wu. Detection and significance of anti-neutrophil cytoplasmic antibodies [J]. Ningxia Medical Journal, 2006, 28 (6): 435-436. DOI: 1001-5949(2006)06-0435-02.
[10]
Dolman KM, Gans RO, Vervaat TJ, et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy [J]. Lancet, 1993:, 342: 651-652. DOI: 10.1016/0140-6736(93)91761-A.
[11]
Wei Yun, Tang Wei: 1 case of anti-neutrophil cytoplasmic antibody-associated vasculitis caused by methimazole. [J]. Zhongnan Pharmaceutical 2019, 17 (11): 2007-2009.
[12]
Shi Zhuo, Fan Zhongmin, Xia Zhengkun, Gao Yuanfu, Sun Tao, Huang Qian, Ren Xianguo, Zhang Pei: Children with secondary anti-neutrophil cytoplasmic antibody-associated microangiitis caused by propylthiouracil: a case report and literature review. [J]. Clinical Pediatrics 2012, 30 (04): 316-318.
[13]
Gao Hongwei. Evaluation of the efficacy and safety of antithyroid drugs in thyroid diseases [J]. Drug and Clinical Medicine, 2015, 12 (9): 35-39.
[14]
Sera N, Ashizawa K, Ando T, et al. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves′ disease [J]. Thyroid, 2000, 10: 595-599. DOI: 10.1089/thy.2000.10.595.
[15]
Liu Chao, Jiang Lin. Recognition of adverse reactions to antithyroid drugs [J]. Chinese Journal of Endocrinology and Metabolism, 2011, 27 (6): 529-532. DOI: 10.3760/cma.j.issn.1000-6699.2011.06.022.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186